CRISPR Therapeutics reported a quarterly loss of $1.28 per share, wider than the Zacks consensus estimate for a $1.14 loss. The result was still an improvement from a $1.58 per-share loss a year ago, but the miss versus expectations is modestly negative. The article contains no revenue, guidance, or other operating details.
CRISPR Therapeutics reported a quarterly loss of $1.28 per share, wider than the Zacks consensus estimate for a $1.14 loss. The result was still an improvement from a $1.58 per-share loss a year ago, but the miss versus expectations is modestly negative. The article contains no revenue, guidance, or other operating details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.18
Ticker Sentiment
